Bal Pharma Limited

BSE:524824 Stock Report

Market Cap: ₹1.9b

Bal Pharma Past Earnings Performance

Past criteria checks 5/6

Bal Pharma has been growing earnings at an average annual rate of 50.4%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 12.7% per year. Bal Pharma's return on equity is 11.2%, and it has net margins of 2.4%.

Key information

50.4%

Earnings growth rate

49.9%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate12.7%
Return on equity11.2%
Net Margin2.4%
Next Earnings Update14 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Bal Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:524824 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,243776290
30 Jun 243,432766110
31 Mar 243,392746140
31 Dec 233,270356010
30 Sep 233,220325890
30 Jun 233,048245710
31 Mar 233,042265610
31 Dec 222,958295420
30 Jun 222,802434940
31 Mar 222,812564780
31 Dec 212,780724590
30 Jun 212,692594260
31 Mar 212,505474260
31 Dec 202,135-344250
30 Sep 201,936-734380
30 Jun 201,741-954690
31 Mar 201,711-1225080
31 Dec 191,924-525290
30 Sep 192,081-155370
30 Jun 192,206-215190
31 Mar 192,250385190
31 Dec 182,264295790
31 Mar 182,093285430
31 Dec 172,111144870
31 Mar 172,289184710
31 Dec 162,210-34550
30 Sep 162,120134310
30 Jun 162,016163960
31 Mar 161,983143870
31 Dec 151,9594758012
30 Sep 151,9253356712
30 Jun 151,861293270
31 Mar 151,875363360
31 Dec 141,846485429
30 Sep 141,857545359
30 Jun 141,836512920
31 Mar 141,789515129
31 Dec 131,720584448

Quality Earnings: 524824 has high quality earnings.

Growing Profit Margin: 524824's current net profit margins (2.4%) are higher than last year (1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 524824 has become profitable over the past 5 years, growing earnings by 50.4% per year.

Accelerating Growth: 524824's earnings growth over the past year (139.1%) exceeds its 5-year average (50.4% per year).

Earnings vs Industry: 524824 earnings growth over the past year (139.1%) exceeded the Pharmaceuticals industry 20.4%.

Return on Equity

High ROE: 524824's Return on Equity (11.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 07:24
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bal Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution